Key data from the INO-VATE study video

Key data for Besponsa (inotuzumab ozogamicin) from the INO-VATE ALL study

Speaker: Dr. Anna Castleton

Duration: 05:22

Anna Castleton is a Consultant Haematologist at the Christie Hospital, Manchester, a position she has held since 2016. She is additionally the ALL Clinical Lead at the Christie Hospital and Regional Teenage and Young Adult Principal Treatment Centre.  Anna has a special interest in ALL and adolescent and young adult haematology, and is the Principal Investigator for several clinical trials in these areas. She is a member of the National Cancer Research Institute Adult ALL Subgroup and the Childhood Leukaemia Clinicians Network. She has authored a number of peer-reviewed papers and presented at several national and international congresses.

In this video, Dr Castleton discusses the INO-VATE study with particular reference to the following:

  • Besponsa mechanism of action
  • Phase III INO-VATE study1: Besponsa vs. standard chemotherapy
    • Study population and eligibility
    • Study endpoints: Remission Rates and Overall Survival
    • Adverse Event profile
    • Management of hepatic toxicity and veno-occlusive disease and risk factors
    • Bridging to transplantation
    • Number of cycles required to achieve remission rates



1. Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.  

PP-INO-GBR-0287. June 2020